Similar articles

• Phosphodiesterase inhibitors as tools in cyclic nucleotide research: a precautionary comment.

  Wells JN, Kramer GL. Wells JN, et al. Mol Cell Endocrinol. 1981 Jul;23(1):1-9. doi: 10.1016/0303-7207(81)90112-x. Mol Cell Endocrinol. 1981. PMID: 6167475 Review. No abstract available.
• Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart. Structure-activity relationships.

  Van Inwegen RG, Salaman P, St Georgiev V, Weinryb I. Van Inwegen RG, et al. Biochem Pharmacol. 1979 Apr 15;28(8):1307-12. doi: 10.1016/0006-2952(79)90430-1. Biochem Pharmacol. 1979. PMID: 87199 No abstract available.
• Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.

  Glass WF 2nd, Moore JB Jr. Glass WF 2nd, et al. Biochem Pharmacol. 1979 Apr 1;28(7):1107-12. doi: 10.1016/0006-2952(79)90313-7. Biochem Pharmacol. 1979. PMID: 87197 No abstract available.
• Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.

  Polson JB, Krzanowski JJ, Anderson WH, Fitzpatrick DF, Hwang DP, Szentivanyi A. Polson JB, et al. Biochem Pharmacol. 1979 Apr 15;28(8):1391-5. doi: 10.1016/0006-2952(79)90442-8. Biochem Pharmacol. 1979. PMID: 87201 No abstract available.
• Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds.

  Francis SH, Sekhar KR, Ke H, Corbin JD. Francis SH, et al. Handb Exp Pharmacol. 2011;(200):93-133. doi: 10.1007/978-3-642-13443-2_4. Handb Exp Pharmacol. 2011. PMID: 20859794 Review.